KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Income (2020 - 2025)

Historic Net Income for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$162.3 million.

  • Recursion Pharmaceuticals' Net Income fell 6929.22% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 8942.19%. This contributed to the annual value of -$463.7 million for FY2024, which is 4133.16% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Net Income stood at -$162.3 million for Q3 2025, which was down 6929.22% from -$171.9 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Net Income peaked at -$30.5 million during Q1 2021, and registered a low of -$202.5 million during Q1 2025.
  • For the 5-year period, Recursion Pharmaceuticals' Net Income averaged around -$92.5 million, with its median value being -$76.7 million (2023).
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 15393.85% in 2021, then skyrocketed by 612.38% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Net Income (Quarter) stood at -$65.0 million in 2021, then grew by 6.12% to -$61.0 million in 2022, then crashed by 52.5% to -$93.0 million in 2023, then crashed by 92.38% to -$178.9 million in 2024, then increased by 9.31% to -$162.3 million in 2025.
  • Its last three reported values are -$162.3 million in Q3 2025, -$171.9 million for Q2 2025, and -$202.5 million during Q1 2025.